Heparin Anti-Xa Unit Converter
Heparin Anti-Xa Unit Converter
Convert heparin anti-Xa activity between IU/mL and IU/L, with the target ranges separated by drug and by sample — because the assay must be calibrated for the heparin being given, and a result read against the other drug’s range is a real error.
Heparin Anti-Xa converter
Anti-Xa activity unitsAnti-Xa 0.5 IU/mL, patient on a therapeutic unfractionated heparin infusion
The units, and the calibration that decides everything
IU/L = IU/mL × 1,000
no molar unit exists — heparin is a heterogeneous polysaccharide measured by activity against a WHO standard, not by mass or amount of substance
- IU/mL = U/mL
- international units of anti-factor Xa activity per millilitre, the unit every published heparin target is written in. The two spellings are the same thing, so no arithmetic is needed between them
- IU/L
- used by a minority of reporting systems: 0.5 IU/mL is 500 IU/L. A pure factor of a thousand
- why there is no molar or mass unit
- heparin is not a single molecule. It is a mixture of sulphated glycosaminoglycan chains of varying length and sulphation, so it has no defined molecular weight and a milligram of one preparation is not equivalent to a milligram of another. Potency is therefore defined functionally, in international units against a WHO International Standard — which is also why unfractionated and low-molecular-weight heparin doses cannot be interconverted
- the calibrator
- the single most important thing on this page. An anti-Xa assay is calibrated with a curve made from a specific heparin, and the curves for unfractionated and low-molecular-weight heparin differ. Running a sample from a patient on enoxaparin against an unfractionated heparin calibration, or reporting either result against the other’s target range, produces a number that looks valid and means something else. The request must state which drug the patient is receiving
- timing
- for unfractionated heparin by continuous infusion the level can be checked at any time once steady state is reached, conventionally six hours after starting or after a rate change. For low-molecular-weight heparin, timing is everything: a peak is drawn about four hours after a dose (sources vary between three to four and four to six hours), a trough just before the next one, and sampling should be at steady state after at least three doses
Worked example
Anti-Xa 0.5 IU/mL, patient on a therapeutic unfractionated heparin infusion
0.5 IU/mL = 0.50 U/mL — the same activity written the other way
0.5 × 1,000 = 500 IU/L, for reports that use the litre
0.50 IU/mL sits inside the 0.3–0.7 IU/mL target for a therapeutic unfractionated heparin infusion
The same number read against the wrong target changes meaning completely. 0.50 IU/mL is mid-range for an unfractionated heparin infusion, at the very bottom of the 0.5–1.0 range for a twice-daily therapeutic low-molecular-weight heparin peak, and frankly subtherapeutic against the 1.0–2.0 range for a once-daily therapeutic peak
Worse, the same sample run against the wrong calibration gives a different number, not just a different comparison — which is why the request has to say which heparin the patient is on
And for low-molecular-weight heparin the timing has to be right before any of it applies: a sample drawn eight hours after a dose is neither a peak nor a trough, and one drawn after the first dose is not at steady state
Targets by drug and sample — the reason this page has no single range
| Drug and regimen | Sample | Target (IU/mL) | IU/L equivalent |
|---|---|---|---|
| Unfractionated heparin, therapeutic intravenous infusion | any time at steady state | 0.3 – 0.7 | 300 – 700 |
| LMWH therapeutic, twice daily (e.g. enoxaparin 1 mg/kg 12-hourly) | peak, about 4 h after a dose | 0.5 – 1.0 | 500 – 1,000 |
| LMWH therapeutic, once daily (e.g. enoxaparin 1.5 mg/kg daily) | peak, about 4 h after a dose | 1.0 – 2.0 | 1,000 – 2,000 |
| LMWH, either regimen | trough, just before the next dose | below 0.5 (one laboratory quotes below 0.4) | below 500 |
| LMWH prophylactic dosing | — | no established target range | — |
Anti-Xa or APTT? What each one can do
| APTT ratio | Anti-Xa | |
|---|---|---|
| What it measures | Global clotting time of the intrinsic and common pathways | Heparin’s specific inhibition of factor Xa |
| Works for LMWH? | No — low-molecular-weight heparin barely prolongs the APTT | Yes, and it is the only practical option |
| When it is unreliable | Lupus anticoagulant (falsely prolonged), high factor VIII in acute inflammation (falsely short), factor deficiencies, warfarin, liver disease, DIC | Interference from direct oral anticoagulants, high bilirubin or triglycerides in some assays, and the wrong calibrator |
| Availability and turnaround | Universal, minutes | Not in every laboratory, often batched, slower |
| Effect of antithrombin deficiency | Fails to prolong — heparin resistance looks like under-dosing | Also reduced, but the discrepancy between a normal-looking APTT and the dose given is the clue |
When a low-molecular-weight heparin level is worth measuring
| Situation | Why | Sample |
|---|---|---|
| Significant renal impairment | LMWH is cleared renally and accumulates as the glomerular filtration rate falls | Peak, after at least three doses |
| Extremes of body weight | Fixed or weight-based dosing is unpredictable at both extremes of weight | Peak |
| Pregnancy | Volume of distribution and renal clearance both change through gestation | Peak, per local obstetric protocol |
| Neonates and infants | Antithrombin is physiologically low and dose requirements differ substantially from adults | Peak, per local paediatric protocol |
| Unexpected bleeding or thrombosis on treatment | To establish whether the drug level explains the event | Timed sample, stating the dose time |
| Routine therapeutic dosing in an average adult | Not indicated — monitoring is not recommended and does not improve outcomes | — |
One assay, several drugs, and the calibration that has to match
Heparin anti-Xa activity is reported in international units per millilitre, and IU/mL and U/mL are the same thing. A minority of reporting systems use IU/L, which is the same number multiplied by a thousand, so 0.5 IU/mL is 500 IU/L. That is the whole of the unit arithmetic, and there is no mass or molar alternative to convert to. Heparin is not a molecule but a family of sulphated glycosaminoglycan chains of varying length and sulphation, with no defined molecular weight, so its potency can only be defined functionally — in international units against a WHO International Standard. That is also why doses of unfractionated and low-molecular-weight heparin cannot be interconverted, and why milligrams of enoxaparin and units of unfractionated heparin are not comparable quantities.
The essential point about the assay follows from the same fact. An anti-Xa result is read off a calibration curve constructed from a specific heparin preparation, and the curves for unfractionated and low-molecular-weight heparin are not the same. A sample from a patient on enoxaparin, run against an unfractionated heparin calibration, produces a plausible-looking number that does not correspond to the published low-molecular-weight heparin ranges — and reporting a result from one drug against the other drug’s target range is a genuine and recurring error in practice. The request form therefore has to state which heparin the patient is receiving, and the laboratory has to have the corresponding calibration available. A result whose calibrator is unknown is uninterpretable no matter how precise it looks.
Timing is the other half of it, and it matters far more for low-molecular-weight heparin than for unfractionated. An unfractionated heparin infusion runs continuously, so once steady state is reached — conventionally about six hours after starting or after a rate change — a sample can be taken at any time, and the therapeutic target is 0.3 to 0.7 IU/mL. Low-molecular-weight heparin is given intermittently, so the level depends entirely on where in the dosing interval the blood was taken. The convention is a peak about four hours after the dose, at steady state after at least three doses; published sampling windows differ, with some sources specifying three to four hours and others four to six with sampling at five, so follow the laboratory’s own instruction. The targets then differ by regimen: about 0.5 to 1.0 IU/mL for a twice-daily therapeutic peak and 1.0 to 2.0 IU/mL for a once-daily therapeutic peak, with a trough below 0.5. This page offers those as separate selectable groups because averaging them would produce a band that is wrong for each. It offers no range at all for prophylactic dosing, because none could be verified from a retrievable primary source and routine monitoring of prophylaxis is not recommended.
What anti-Xa is genuinely good for is the situation where the activated partial thromboplastin time cannot be trusted. The APTT is a global clotting time, and two common problems wreck it as a heparin monitor. A lupus anticoagulant prolongs the baseline, so the ratio is elevated before any heparin is given and dose adjustments made on it lead to systematic under-dosing. A high factor VIII level, ordinary in acute inflammation, shortens the APTT, so the ratio stays stubbornly low and the infusion is pushed up towards bleeding. In both cases the anti-Xa level is the measurement to use. For low-molecular-weight heparin the APTT is not a candidate at all, since the drug barely prolongs it. Two further cautions are worth carrying: a level that will not rise despite escalating unfractionated heparin should raise antithrombin deficiency and heparin resistance, because heparin works through antithrombin — see the antithrombin activity converter — and no anti-Xa level, however reassuring, addresses heparin-induced thrombocytopenia. A platelet count falling by more than half from baseline four to ten days into heparin exposure needs a 4Ts score and a decision about stopping heparin altogether.
Frequently asked questions
What is the therapeutic anti-Xa range for heparin?
It depends on the drug and the sample, which is why this page will not quote one figure. A therapeutic unfractionated heparin infusion targets 0.3–0.7 IU/mL. For low-molecular-weight heparin the peak, about four hours after a dose, is 0.5–1.0 IU/mL on twice-daily therapeutic dosing and 1.0–2.0 IU/mL on once-daily therapeutic dosing, with a trough below 0.5 IU/mL. Averaging those would give a band that is wrong for every regimen. Follow your local protocol.
Why does the anti-Xa assay have to be calibrated for the specific heparin?
Because the result is read off a calibration curve built from a particular heparin preparation, and the curves for unfractionated and low-molecular-weight heparin differ. A sample from a patient on enoxaparin run against an unfractionated heparin calibration gives a number that does not correspond to the published low-molecular-weight heparin ranges, and reporting one drug’s result against the other’s target range is a real and recurring error. The request has to state which heparin the patient is receiving.
When should a low-molecular-weight heparin anti-Xa level be taken?
At steady state, after at least three doses, and timed relative to the dose. A peak is conventionally drawn about four hours after a dose — published windows vary between three to four and four to six hours, so follow your laboratory’s instruction — and a trough just before the next dose. A sample taken at some other point is neither, and cannot be compared with a peak or trough target. Always record the dose time and the sampling time on the request.
Why measure anti-Xa instead of the APTT?
Because the APTT is unreliable in several common situations and useless for low-molecular-weight heparin. A lupus anticoagulant prolongs the baseline APTT, making the ratio meaningless and leading to under-dosing; a high factor VIII level in acute inflammation shortens it, driving doses upwards towards bleeding. Factor deficiencies, warfarin, liver disease and disseminated intravascular coagulation all interfere too. Low-molecular-weight heparin barely prolongs the APTT at all, so anti-Xa is the only practical option there.
Does low-molecular-weight heparin need routine monitoring?
No. It was developed to be given without monitoring, and its anti-Xa targets are largely derived from observed levels and correlation with the APTT rather than from trials showing that adjusting to them improves outcomes. Measurement is reserved for patients in whom the pharmacokinetics are unpredictable: significant renal impairment, extremes of body weight, pregnancy, neonates and infants, and unexpected bleeding or thrombosis on treatment.
My patient needs huge doses of heparin and the level stays low — why?
Consider antithrombin deficiency and heparin resistance. Heparin has almost no anticoagulant activity of its own and works by accelerating antithrombin; with little antithrombin available, escalating the infusion achieves very little. Other contributors include a high factor VIII level, raised heparin-binding proteins in acute inflammation and large-volume heparin loss. The answer is not simply more heparin: check the antithrombin activity, consider replacement where indicated, and consider an anticoagulant that does not depend on antithrombin.
Related calculators
References
- UW Medicine Anticoagulation Services. Monitoring of antithrombotic therapy. Therapeutic range for intravenous unfractionated heparin 0.3–0.7 units/mL; observed peak anti-Xa for twice-daily LMWH 0.5–1 units/mL and for 1.5 mg/kg once-daily LMWH 1–2 units/mL; expected trough below 0.5 units/mL; LMWH peaks drawn 3–4 hours after a dose.
- University of Michigan MLabs. UFH Anti-Xa and LMWH Anti-Xa test catalogue entries. UFH therapeutic range 0.3–0.7 IU/mL with a critical value above 1.0 IU/mL; enoxaparin 1 mg/kg twice daily peak 0.5–1.0 IU/mL and 1.5 mg/kg daily peak 1.0–2.0 IU/mL, drawn 4–6 hours post dose at steady state after three doses, trough below 0.4 IU/mL; critical value above 2.0 IU/mL.
- Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S–e43S.
- Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546–558.
- Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49–56.
- Ignjatovic V, Summerhayes R, Newall F, Monagle P. Therapeutic range for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost. 2006;4(10):2280–2282.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.